The VHL/HIF axis in clear cell renal carcinoma

被引:282
|
作者
Shen, Chuan
Kaelin, William G., Jr.
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02215 USA
关键词
Kidney cancer; von Hippel-Lindau; Hypoxia; Angiogenesis; VEGF; HYPOXIA-INDUCIBLE FACTOR; EPIDERMAL-GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; MYELOID-LEUKEMIC-CELLS; PAS DOMAIN PROTEIN; PHASE-II TRIAL; FACTOR RECEPTOR; FACTOR-ALPHA; HISTONE DEMETHYLASES; INTERFERON-ALPHA;
D O I
10.1016/j.semcancer.2012.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of the VHL tumor suppressor protein (pVHL) is a common event in clear cell renal carcinoma, which is the most common form of kidney cancer. pVHL performs many functions, including serving as the substrate recognition module of an ubiquitin ligase complex that targets the alpha subunits of the heterodimeric HIF transcription factor for proteasomal degradation. Deregulation of HIF2 alpha appears to be a driving force in pVHL-defective clear cell renal carcinomas. In contrast, genetic and functional studies suggest that HIFI a serves as a tumor suppressor and is a likely target of the 14q deletions that are characteristic of this tumor type. Drugs that inhibit HIF2 alpha, or its downstream targets such as VEGF, are in various stages of clinical testing. Indeed, clear cell renal carcinomas are exquisitely sensitive to VEGF deprivation and four VEGF inhibitors have now been approved for the treatment of this disease. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:18 / 25
页数:8
相关论文
共 50 条
  • [1] VHL inactivation in sporadic clear cell renal carcinoma
    Mikhaylenko, D. S.
    Kurynin, R. V.
    Popov, A. M.
    Karyakin, O. B.
    Enikeev, M. E.
    Alyaev, Yu. G.
    Nemtsova, M. V.
    Zaletayev, D. V.
    MOLECULAR BIOLOGY, 2008, 42 (01) : 64 - 69
  • [2] VHL inactivation in sporadic clear cell renal carcinoma
    D. S. Mikhaylenko
    R. V. Kurynin
    A. M. Popov
    O. B. Karyakin
    M. E. Enikeev
    Yu. G. Alyaev
    M. V. Nemtsova
    D. V. Zaletayev
    Molecular Biology, 2008, 42 : 64 - 69
  • [3] Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma
    Sourbier, Carole
    Srivastava, Gaurav
    Ghosh, Manik C.
    Ghosh, Sanchari
    Yang, Youfeng
    Gupta, Gopal
    DeGraff, William
    Krishna, Murali C.
    Mitchell, James B.
    Rouault, Tracey A.
    Linehan, W. Marston
    ONCOTARGET, 2012, 3 (11) : 1472 - 1482
  • [4] VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma
    Francesca Lessi
    Chiara Maria Mazzanti
    Sara Tomei
    Claudio Di Cristofano
    Andrea Minervini
    Michele Menicagli
    Alessandro Apollo
    Lorenzo Masieri
    Paola Collecchi
    Riccardo Minervini
    Marco Carini
    Generoso Bevilacqua
    Medical Oncology, 2014, 31
  • [5] Investigation of the Role of microRNA Associated with the VHL-HIFα-Dependent Pathway in Patients with Clear Cell Renal Cell Carcinoma
    E. A. Klimentova
    I. R. Gilyazova
    M. A. Bermisheva
    A. M. Blinnikova
    R. I. Safiullin
    A. A. Izmailov
    B. Yang
    V. N. Pavlov
    E. K. Khusnutdinova
    Russian Journal of Genetics, 2020, 56 : 363 - 369
  • [6] VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression
    Ji, Jing
    Xu, Yuxin
    Xie, Mengru
    He, Xingbei
    Ren, Dexu
    Qiu, Teng
    Liu, Wenwen
    Chen, Zefeng
    Shi, Wen
    Zhang, Zhen
    Wang, Xiujun
    Wang, Weiling
    Ma, Jinming
    Qian, Qilan
    Jing, Aixin
    Ma, Xinhui
    Qin, Jingting
    Ding, Yuanyuan
    Geng, Ting
    Yang, Jiayan
    Sun, Zhichao
    Liu, Wei
    Liu, Shunfang
    Liu, Bin
    CELL DEATH & DISEASE, 2023, 14 (02)
  • [7] Investigation of the Role of microRNA Associated with the VHL-HIFα-Dependent Pathway in Patients with Clear Cell Renal Cell Carcinoma
    Klimentova, E. A.
    Gilyazova, I. R.
    Bermisheva, M. A.
    Blinnikova, A. M.
    Safiullin, R., I
    Izmailov, A. A.
    Yang, B.
    Pavlov, V. N.
    Khusnutdinova, E. K.
    RUSSIAN JOURNAL OF GENETICS, 2020, 56 (03) : 363 - 369
  • [8] VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression
    Jing Ji
    Yuxin Xu
    Mengru Xie
    Xingbei He
    Dexu Ren
    Teng Qiu
    Wenwen Liu
    Zefeng Chen
    Wen Shi
    Zhen Zhang
    Xiujun Wang
    Weiling Wang
    Jinming Ma
    Qilan Qian
    Aixin Jing
    Xinhui Ma
    Jingting Qin
    Yuanyuan Ding
    Ting Geng
    Jiayan Yang
    Zhichao Sun
    Wei Liu
    Shunfang Liu
    Bin Liu
    Cell Death & Disease, 14
  • [9] Implication of VHL, ERK5, and HIF-lalpha in clear cell renal cell carcinoma: Molecular basis
    Serrano-Oviedo, Leticia
    Gimenez-Bachs, Jose M.
    Nam-Cha, Syongh Y.
    Cimas, Francisco J.
    Garcia-Cano, Jesus
    Sanchez-Prieto, Ricardo
    Salinas-Sanchez, Antonio S.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (03) : 114.e15 - 114.e22
  • [10] VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma
    Lessi, Francesca
    Mazzanti, Chiara Maria
    Tomei, Sara
    Di Cristofano, Claudio
    Minervini, Andrea
    Menicagli, Michele
    Apollo, Alessandro
    Masieri, Lorenzo
    Collecchi, Paola
    Minervini, Riccardo
    Carini, Marco
    Bevilacqua, Generoso
    MEDICAL ONCOLOGY, 2014, 31 (03)